N/A
N=696
Pragmatic Obstructive Sleep Apnea Weight Loss Trial Assessing Effectiveness and Reach
Obesity · Sleep Apnea, Obstructive
Bottom Line
View on ClinicalTrials.gov: NCT05104450 ↗Enrolled (actual)
696
Serious AEs
13.5%
Results posted
Oct 2025
Primary outcome: Primary: Change in Sleep-related Quality of Life — 1.43; 0.93 units on a scale — p=0.001
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- lifestyle intervention (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- Aug 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Sleep-related Quality of Life |
1.43; 0.93 | 0.001 sig |
| PRIMARY Change in Weight |
-2.10; -0.88 | 0.037 sig |
| SECONDARY Cardiovascular Risk Scores |
0.35; -0.14 | 0.074 |
| SECONDARY PROMIS - Sleep Disturbance Survey Change |
-3.88; -3.44 | 0.229 |
| SECONDARY PROMIS - Sleep Related Impairment Survey Change |
-5.78; -4.76 | 0.116 |
| SECONDARY Systolic Blood Pressure From VA Medical Record |
-0.67; -2.25 | 0.968 |
| SECONDARY Treatment Usage Per Day |
1.47; 1.23 | 0.317 |
| SECONDARY Apnea Hypopnea Index 1b Criteria |
13.77; 16.49 | 0.061 |
| SECONDARY Longer-term Change in Weight |
-2.64; -1.98 | 0.469 |
| SECONDARY Short-term Change in Sleep-related Quality of Life |
1.30; 0.67 | <0.001 sig |
| SECONDARY Longer-term Change in Sleep-related Quality of Life |
1.29; 0.96 | 0.031 sig |
| SECONDARY Global Rating of Change |
2.91; 3.10 | 0.107 |
| SECONDARY Change in Self-reported Well-being |
7.96; 5.24 | 0.065 |
| SECONDARY Cardiovascular Risk Scores |
0.35; -0.14 | 0.074 |
| SECONDARY PROMIS - Sleep Disturbance Survey Change |
-3.88; -3.44 | 0.229 |
| SECONDARY PROMIS - Sleep Disturbance Survey Change |
-3.88; -3.44 | 0.229 |
| SECONDARY PROMIS - Sleep Related Impairment Survey Change |
-5.78; -4.76 | 0.116 |
| SECONDARY PROMIS - Sleep Related Impairment Survey Change |
-5.78; -4.76 | 0.116 |
| SECONDARY Systolic Blood Pressure From VA Medical Record |
-0.67; -2.25 | 0.968 |
| SECONDARY Diastolic Blood Pressure From VA Medical Record |
0.13; -1.74 | 0.212 |
| SECONDARY Diastolic Blood Pressure From VA Medical Record |
0.13; -1.74 | 0.212 |
| SECONDARY Treatment Usage Per Day |
1.47; 1.23 | 0.317 |
| SECONDARY Treatment Usage Per Day |
1.47; 1.23 | 0.317 |
| SECONDARY Global Rating of Change |
2.91; 3.10 | 0.107 |
| SECONDARY Global Rating of Change |
2.91; 3.10 | 0.107 |
| SECONDARY Change in Self-reported Well-being |
7.96; 5.24 | 0.065 |
| SECONDARY Change in Self-reported Well-being |
7.96; 5.24 | 0.065 |
| SECONDARY Apnea Hypopnea Index 1a Criteria |
20.06; 23.23 | 0.041 sig |
Summary
Prevalent obesity related conditions like obstructive sleep apnea (OSA) represent an important opportunity to improve population health. OSA reduces quality of life and is associated with greater risk for cardiovascular disease. Although obesity is the single greatest reversible risk factor for OSA, patients with OSA and obesity rarely receive weight loss care to reverse OSA and other serious comorbidities. Efficacy trials reinforce that time and resource intensive lifestyle-based weight loss programs improve weight and physiologic measures of OSA severity (apnea hypopnea index, AHI). However, there are barriers to translating these findings into meaningful gains for population health. To meet these challenges, the investigators propose a pragmatic trial of proactively offering a remote video-based and self-directed lifestyle-based weight loss intervention with remote coaching to patients with OSA. The investigators primary aim is to test the effectiveness of a proactively delivered and pragmatic lifestyle intervention to improve co-primary endpoints of sleep-related quality of life and weight among patients with OSA and obesity. Secondarily, the investigators will compare additional outcomes between groups including cardiovascular risk scores, sleep symptoms, AHI, well-being, and global ratings of change. Finally, the investigators will also conduct an implementation process evaluation informed by the RE-AIM framework to identify barriers and facilitators to widespread implementation.
The investigators will identify patients with OSA and obesity nationwide (n=696) in VA using data from the VA's Corporate Data Warehouse (CDW), and the investigators will contact potentially eligible patients. After confirming eligibility and consent, the investigators will randomly assign subjects to receive the study's lifestyle intervention or usual care alone. The study uses CDW to assess weight change. Subjects will complete questionnaires at baseline at 3, 12 and 21 months after randomization. The lifestyle intervention in POWER focuses on gradual lifestyle behavior change aimed at improving eating habits and increasing physical activity. It encourages participants to gradually achieve and maintain a 5-10% loss of baseline body weight and at least 150 minutes of moderate-intensity physical activity, such as brisk walking, each week. The lifestyle intervention program consists of watching one video, completing corresponding written self-guided learning materials, and tracking food intake and physical activity each week for the first 12 weeks, then working through 10 additional written handouts and continued food and activity tracking for the next nine months. Intervention participants will have access to a lifestyle coach as desired for the full 12-month intervention period.
Eligibility Criteria
Inclusion Criteria
- Diagnosis of obstructive sleep apnea (OSA) on sleep study (sleep provider confirmed)
- Recent body mass index between 30.0-44.9 kg/m2 and at least one additional plausible BMI in last 12 months
- Access to DVD player, computer, and/or internet
- Able to participate fully in all study protocol/procedures including informed consent
Exclusion Criteria
- Inability to speak, read, or understand English
- Recent or active weight loss interventions including use of prescription weight-loss medications, participation in group or individual weight loss programs provided by trained personnel, and prior bariatric surgery or plans for bariatric surgery during the study period.
- Expected weight loss because of alternate explanations such as from illness
- High variability in weight due to fluctuations in volume status (e.g. ascites - liver disease, chronic heart failure)
- Safety and/or adherence concerns due to severe physical or mental health issues, or life expectancy <24 months
- Pregnant, lactating, or planning to become pregnant during the study period
- Participation in other intervention studies
Data sourced from ClinicalTrials.gov (NCT05104450). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.